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Abstract: As the economic pressures increase on healthcare systems around the world due to aging populations, chronic 
diseases, expanding patient populations in emerging markets and advances in medical technology, it is crucial that we 
focus on developing and delivering innovative and quality medicines with true medical value to patients around the 
world in a more collaborative, quality-focused and cost-effective manner. 
An important component to this mission across the biopharmaceutical industry is identifying and solving common is-
sues that compromise the success of a clinical development program – the shared pathway to safer and more clinically 
meaningful medicines. However, subject recruitment challenges, data collection and follow-up issues, identification of 
high-quality trial sites, and lack of successfully achieving study timelines continue to stress clinical trial operations 
teams across companies. Although there has been progressing across this range of roadblocks by individual companies, 
the underlying economics continue to threaten the research and development (R&D) business model. 
Failure to solve these key issues will affect all parties involved in the clinical trial enterprise: patients, clinical inves-
tigators, health authorities, academia, tax-payers and the sponsor companies. The question remains whether a deep and 
broad collaborative effort that stretches across the clinical development arena—one that is charged with a common goal 
of improving quality, enhancing the investigator and patient experience, reducing costs and sharing data—can be a 
catalyst for success. With encouraging signs already realised, the operation of TransCelerate BioPharma Inc., a 
non-profit organisation created to improve the health of people around the world by accelerating and enhancing the 
R&D of innovative new therapies will test this premise. 
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1. Introduction 
ince its launch in 2012, TransCelerate Bio-
Pharma’s membership has grown to include 20 
biopharmaceutical companies: AbbVie[1], Acta-
vis + Allergan[2], Amgen[3], AstraZeneca[4], Astellas[5], 
Biogen[6], Boehringer Ingelheim[7], Bristol-Myers 
Squibb[8], EMD Serono[9], GlaxoSmithKline[10], John-
son & Johnson[11], Eli Lilly[12], Medgenics[13], Mer-
ck[14], Novo Nordisk[15], Pfizer[16], Roche[17], Sanofi[18], 
Shionogi[19], and UCB Pharma[20]—all with a shared 
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development (R&D) of important new therapies. 
Bringing such highly recognised organisations togeth-
er into an environment where collaboration for the 
betterment of all is the focus, promises to create a 
greater outcome than if we all worked in silos.  
As a group, we are listening to pain points that are 
common across all of our organisations and finding 
ways to solve them together. The challenge is not in 
recognizing that there are many areas of opportunity 
for improvement in clinical development, but rather in 
identifying which specific areas can we truly make an 
impact in a positive manner, while respecting the fact 
that we are fierce, independent competitors. One ex-
ample of our focus is to alleviate the duplicative bur-
dens we place on clinical trial sites and their patients. 
Although TransCelerate does not represent the entire 
biopharmaceutical industry, we still feel that we have 
the ability to effectively address some of these 
challenges given the vast array of talent, practical 
experience, and knowledge derived from the number 
of clinical trials its members have conducted and the 
influence that a group comprised of such thought 
leaders will likely have. 
2. Critical Issues and Unmet Needs 
TransCelerate was conceived while the clinical trial 
business model was under intense pressure. As many 
in the industry understand, the status quo for clinical 
trial operations has not been sustainable for a very 
long time: it costs more than $2.6 billion dollars[21] to 
bring one new medicine to physicians and patients. 
This cost structure is negatively impacting the indus-
try’s ability to produce new drugs and maintain or 
increase drug quality. Although most companies have 
initiated their own program to reduce cost and im-
prove quality, the status quo remains an inefficient 
model for all parties involved in the clinical study of 
medicines.  
TransCelerate has focused on improving the rela-
tionships in the clinical development space and sys-
tematically addressing issues that an individual com-
pany could not take on by itself. The list of potential 
ways to influence and impact efficiency, quality, safety, 
and cost, are boundless. However, with a multi-year 
strategic road map in mind, TransCelerate sought a 
path to strategically deliver solutions that could im-
prove the clinical trials execution paradigm serially 
and in parallel. 
3. Accelerating a Paradigm Shift in R&D 
One of TransCelerate’s greatest strengths is the coll-
ective experience, knowledge and passion of the par-
ticipating Member Companies and the people working 
on initiatives such as Clinical Data Standards[22], Site 
Qualification[23], Risk Based Monitoring[24] and more. 
We are proud to engage top R&D leaders from each of 
the Member Companies who provide different expe-
riences, diverse backgrounds and the ability to devel-
op innovative concepts to address shared industry 
challenges.  
Since inception, three of the earliest TransCelerate’s 
initiatives have received significant acknowledgement: 
launching a framework for mutually recognised Good 
Clinical Practice (GCP) training, establishing a rec-
ommended method and approach to high-quality Risk 
Based Monitoring (RBM), and supporting the develo-
pment and launch of industry-wide Therapeutic Area 
Data Standards[25] through a collaboration with the 
Clinical Data Interchange Standards Consortium 
(CDISC)[26], Critical Path Institute (C-Path)[27], Nati-
onal Cancer Institute – Enterprise Vocabulary Service 
(NCI-EVS)[28] and the U.S. Food and Drug Admini-
stration (FDA)[29] as part of the Coalition for Accelera-
ting Standards and Therapies (CFAST)[30].  
In addition, TransCelerate has launched a Drug 
Comparator Network[31] that allows Member Com-
panies who chose to participate, to purchase approved 
drugs directly from each other for clinical trials, 
thereby ensuring a safe, secure and reliable supply of 
comparator drugs. Later this year, TransCelerate will 
launch the Shared Investigator Platform[32], a portal 
that will revolutionise communication between sites 
and sponsors, by providing a single sign-on capability 
for clinical investigators to access study-related infor-
mation across multiple sponsors. This will create sig-
nificant improvements in the communication channels 
between sites and sponsors, by easing the burden of 
site staff and improving quality through more harmo-
nised IT solutions. 
4. Key Milestones  
Over the last three years, the RBM Initiative[33] has 
been one of the areas where we have made a signifi-
cant impact within the industry. RBM is an adaptive 
approach to clinical trial monitoring that directs the 
focus of monitoring and activities to the evolving 
areas of greatest need with the most potential to affect 
patient safety and data quality. Supporting infrastruc-
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ture helps to enable RBM within Member Company’s 
organisation by using common tools and triggers to 
identify risk, as well as the standard categorisation of 
low, medium and high risk trials. With uniform, in-
dustry-wide guidelines and supporting infrastructure 
for risk reporting, RBM’s Methodology can both en-
hance patient safety and ensure the quality of clinical 
data. 
Each participant of the clinical trial continuum will 
experience the benefits of RBM. Sponsors are able to 
allocate resources more efficiently and ensure subject 
safety, data integrity and GCP compliance, while 
patients are provided a safer clinical trial environment 
due to focus from sponsor and site on critical data and 
processes. By reducing the mass generation of queries 
issued months or years after data was originally 
generated, we decrease site personnel time checking 
data elements and allow them more time to focus on 
their patients. Regulatory bodies also potentially ben-
efit from working closely with each other to ensure 
alignment on guidance documents. Before TransCele-
rate took on this challenge, no model framework that 
enabled organisations to successfully deploy and scale 
RBM existed.  
Most recently, TransCelerate released RBM’s Vo-
lume 3 Monitoring Update[34] which outlined three 
publications that further the understanding of RBM, 
quantitative performance metrics, external engage-
ment updates and 2015 deliverables. The volume 3 
publication reflects TransCelerate’s commitment to 
continuously refining and improving this and other 
initiatives for optimal results to the industry.  
Another TransCelerate initiative that is addressing 
the burdens placed on clinical investigator sites is the 
Site Qualification & Training Initiative[35]. Tradition-
ally, clinical trial investigators and sites—for each 
company and often for each trial—are required to 
complete questionnaires, forms and similar training 
courses to prepare for trial participation. GCP training 
and collection of non-study specific information are 
pain points for investigators and sites as well as bio-
pharmaceutical companies. Rather than going to the 
investigator and training them in GCP methods mul-
tiple times, in multiple ways, we can now cross-rec-
ognize different pharmaceutical companies’ trainings 
and not duplicate efforts. The mutual recognition of 
GCP training[36] allows clinical trial investigators and 
other site personnel who have completed any GCP 
training program that meets minimum criteria based 
on ICH principles[37], to have that training be accepted 
by participating Member Companies. 
As of last year, TransCelerate completed the evalu-
ation of 130 professional GCP training courses from 
over 110 unique providers meeting the minimum cri-
teria[38] across the participating TransCelerate Member 
Companies. We also launched a feature on the Trans-
Celerate website to simplify the self-attestation 
process[39] for training providers. By reducing time 
spent on GCP training, we are working together to 
improve study start-up times, streamline sponsor col-
laboration with sites and ultimately improve clinical 
trial site quality.  
5. Future Opportunities for Clinical Trials 
5.1 Clinical Data Transparency 
A major movement that we are experiencing and will 
expand upon in the coming years is increasing trans-
parency when sharing clinical data. Cooperation acr-
oss sponsor companies, investigators, academia and 
clinical research organisations is widely recognised as 
a key indicator in the acceleration of drug develop-
ment. Indeed, biopharmaceutical companies and th-
ought leaders in the field are coming out in support of 
this. The Institute of Medicine released a report in 
January titled “Sharing Clinical Trial Data: Maximi-
zing Benefits, Minimizing Risk,”[40] that provided the 
value of data sharing and guidelines and roles required 
for success. TransCelerate has positioned itself to be a 
leader in this space with several initiatives that aim to 
make it easier to prepare, review, interpret, access and 
share clinical data such as Clinical Data Standards[41], 
the Shared Investigator Platform[42], Placebo and 
Standard of Care Data-Sharing[43] and Clinical Data 
Transparency[44].  
5.2 Technology Advancements 
Technology advances bring new opportunities for cost 
reduction, improved decision making and multi-cha-
nnel communication between researchers, sponsors, 
investigators and patients. It is expected that a major-
ity of biopharmaceutical companies are researching on 
how best to integrate mobile, social, cloud and big 
data in order to help revolutionise R&D divisions. 
TransCelerate is integrating some of these technology 
opportunities through initiatives such as electronic 
labels (eLabels)[45]. Today’s labelling information pro-
vided with investigational medicines are not leverag-
ing the range of technologies currently available that 
can provide truly engaging content for patients. What 
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TransCelerate is aspiring to do with the e-Labels Ini-
tiative, is to leverage the different ways in which in-
formation can be delivered through the use of tech-
nology, such as mobile, where it is easier to con-
sume—whether it is the printed word, or multimedia 
or otherwise[46]. Ultimately, the e-Labels Initiative will 
work to enhance label quality and utility for patients, 
provide more consistent labelling approaches for clin-
ical trial sites, potentially reduce clinical labelling 
timelines and provide cost efficiencies for sponsors.  
5.3 Collaboration 
Historically, R&D in the biopharmaceutical industry 
has been on a linear plot: companies identify targets, 
select candidates, review toxicology, test for the first 
time in humans, establish proof of concept, move 
through research phases and so forth. The information 
learnt along the way is not optimally utilised to im-
prove the processes—even within individual compa-
nies. As some have recognised, if sponsors had shared 
key learning, then the information received, coupled 
with real world data and evidence from our clinical 
trials, could reinforce circles of learning. In fact, a 
recent article from Deloitte highlighted some of the 
key areas of collaboration between biopharmaceutical 
companies that substantially impacted processes, such 
as pooling resources to share R&D costs and improve 
time to market for new drugs by standardising deve-
lopment cycles from early trials through commercial-
isation; filling gaps in product pipelines by co-deve-
loping innovative products and sharing costs and 
profits evenly; hedging R&D-related risk in discovery 
and early stage development by forming alliances; and 
working with companies outside the traditional life 
sciences industry to offer a better and more well-roun-
ded standard of healthcare[47]. As such, TransCelerate 
provides a platform that can foster and facilitate these 
and other initiatives to increase the development of 
new drugs through more efficient R&D processes. 
6. Conclusion  
To date, TransCelerate has benefited from an unprec-
edented sense of purpose among its member compa-
nies, as well as clear leadership. The formula driving 
TransCelerate forward is because we are comprised of 
some of the most passionate and innovative thinkers in 
R&D, from some of the world’s most successful bio-
pharmaceutical organisations, who have fundamen-
tally recognised that working together can often be 
much more productive and efficient than working 
apart. However, our mission would prove unsuccess-
ful if it were not for our partnerships with a large array 
of external stakeholders that enabled us to create value 
for the biopharmaceutical industry[48]. 
The joint efforts have resulted in an ongoing dialo-
gue in over 20 countries, and engagement with major 
health authorities around the world. We are truly wit-
nessing global momentum and are poised—excited 
and ready—for the next phase of our mission.  
Although our focus has been on improving the way 
clinical trial sites operate and how investigators and 
staff function to make a clinical trial as efficient and 
safe as possible, in the future, we will look to expand 
our horizon. While our interface with patients is not 
direct, we are now increasing our efforts in defining 
needs for patient-centred activities during clinical tri-
als. Lastly, we see an opportunity to extend our remit 
and hope to successfully take our approach to the 
non-clinical space of R&D.  
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